Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Analysts expect LiveOne to report an earnings per share (EPS) of $-0.05. The announcement from LiveOne is eagerly anticipated ...

Analysts estimate that Kamada will report an earnings per share (EPS) of $0.09. The announcement from Kamada is eagerly ...

The stock market today has seen some strong movements in a number of companies across different sectors. Several stocks have ...

Kohl's KSS stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75. Please ...

Below In a recent AI Investor podcast discussion, financial analysts Austin and Eric Bleeker analyzed the current state of Marvell Technology (Nasdaq: MRVL), a leading AI chip company that has ...

Highway Infrastructure shares will list on NSE and BSE at 10 AM. Highway Infrastructure IPO latest GMP is indicating a strong ...

Venture Global Inc.’s crown as worst US public markets debutant this year is undented after the liquefied natural gas exporter reported second quarter earnings.

Beef prices have eased a shade in the UK, which the processors are pointing to as justifying a tighter grip on upward ...

XSD offers exposure to 40 U.S. semiconductor stocks with a modified equal-weight approach. Click here for more information on ...

Euro US Dollar, Gold Spot US Dollar, US Dollar Index Futures, Gold Futures. Read 's Market Analysis on Investing.com ...